A Phase 3 interventional study of fluticasone furoate/vilanterol and Placebo in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 34 sites in 4 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-01-11.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, none of them phase 3. fluticasone furoate · Pulmonary Disease, Chronic Obstructive.
Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, this one is the 8th largest by enrollment, is one of 4 that started in 2011, is one of 7 in phase 3, and was the 5th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive are open now, in 2 countries. Recruiting first, the newest first:
Western University, Canada · Sites in Canada
Ages 50–85
National Institute of Respiratory Diseases, Mexico · Sites in Mexico
Ages 35–85 · Women only
By country, each count listing its studies:
fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 646 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 229 across the 25 interventional studies. Of the 21 that completed or were terminated, 15 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 25 have an industry lead sponsor. The 5 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline: 7 open now, 8 under way, 5 of them phase 3. Of 264 finished, 141 (53%) have results posted.
Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 41st largest by enrollment of the 236 interventional ones that give a count, is one of 26 that started in 2011, is one of 65 in phase 3, and was the 121st registered.
GlaxoSmithKline’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2000.
1 of the studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07192016Western University, Canada129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 276 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to investigate the efficacy and safety of fluticasone furoate/vilanterol Inhalation Powder compared with placebo over a 24 weeks treatment period in subjects of Asian ancestry with Chronic Obstructive Pulmonary Disease (COPD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inhaled corticosteroid/long acting beta-agonist
Drug: fluticasone furoate/vilanterol
matching placebo
Drug: Placebo
Drug pages: Fluticasone furoate · Vilanterol
Inhaled corticosteroid/long acting beta-agonist
matching placebo
Mean Change From Baseline in Clinic Visit Pre-dose Trough FEV1 at Day 169
Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 was defined as the pre-dose and pre-bronchodilator FEV1, which was obtained at each clinic visit. Baseline is defined as the mean of the two assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1.Trough FEV1 is defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing at each clinic visit. Change from Baseline was calculated as the average at each clinic visit minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, smoking status at screening (stratum), baseline - mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1, day, day by baseline and day by treatment interactions.
Time frame: Baseline to Day 169
Mean Change From Baseline in Chronic Respiratory Disease Questionnaire Self-administered Standardized (CRQ-SAS) Dyspnea Domain Score at Day 168
CRQ-SAS measures 4 domains (fatigue, emotional function, mastery and dyspnea) of functioning of participants (par.) with COPD: mastery (amount of control the par. feels he/she has over COPD symptoms); fatigue (how tired the par. feels); emotional function (how anxious/depressed the par. feels); and dyspnea (how short of breath the par. feels during physical activities). Each domain is calculated separately and measured on a scale of 1-7 (1=maximum impairment; 7=no impairment). Dyspnea domain score is the mean of all non-missing responses for that domain. Only the dyspnea domain was measured as a secondary outcome. BL scores are the derived scores for each domain and total at Day 1 pre-dose. Change from BL was calculated as the average of the Day 168 values minus the BL value. Analysis performed used a repeated measures model with covariates of treatment, smoking status at screening (stratum), BL (derived scores at Day 1 pre-dose), day, day by BL, and day by treatment interactions.
Time frame: Baseline (BL) and Day 168
| Milestone | Placebo- Run-in | Placebo | FF /VI 50/25 µg OD | FF/VI 100/25 µg OD | FF/VI 200/25 µg OD |
|---|---|---|---|---|---|
| Started | 744 | 0 | 0 | 0 | 0 |
| Completed | 643 | 0 | 0 | 0 | 0 |
| Not completed | 101 | 0 | 0 | 0 | 0 |
| Withdrew: Did not meet continuation criteria | 66 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 28 | 0 | 0 | 0 | 0 |
| Milestone | Placebo- Run-in | Placebo | FF /VI 50/25 µg OD | FF/VI 100/25 µg OD | FF/VI 200/25 µg OD |
|---|---|---|---|---|---|
| Started | 0 | 162 | 160 | 161 | 160 |
| Completed | 0 | 130 | 135 | 138 | 134 |
| Not completed | 0 | 32 | 25 | 23 | 26 |
| Withdrew: Adverse event | 0 | 16 | 7 | 8 | 18 |
| Withdrew: Lack of efficacy | 0 | 4 | 5 | 4 | 3 |
| Withdrew: Protocol violation | 0 | 2 | 0 | 2 | 1 |
| Withdrew: Met protocol-defined stopping criteria | 0 | 2 | 3 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 | 1 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 6 | 9 | 6 | 3 |
Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 was defined as the pre-dose and pre-bronchodilator FEV1, which was obtained at each clinic visit. Baseline is defined as the mean of the two assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1.Trough FEV1 is defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing at each clinic visit. Change from Baseline was calculated as the average at each clinic visit minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, smoking status at screening (stratum), baseline - mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1, day, day by baseline and day by treatment interactions.
| Liters | Placebo | FF/VI 50/25 µg OD | FF/VI 100/25 µg OD | FF/VI 200/25 µg OD |
|---|---|---|---|---|
| Mean Change From Baseline in Clinic Visit Pre-dose Trough FEV1 at Day 169 | -0.027 ± 0.0184 | 0.113 ± 0.0183 | 0.152 ± 0.0181 | 0.167 ± 0.0182 |
CRQ-SAS measures 4 domains (fatigue, emotional function, mastery and dyspnea) of functioning of participants (par.) with COPD: mastery (amount of control the par. feels he/she has over COPD symptoms); fatigue (how tired the par. feels); emotional function (how anxious/depressed the par. feels); and dyspnea (how short of breath the par. feels during physical activities). Each domain is calculated separately and measured on a scale of 1-7 (1=maximum impairment; 7=no impairment). Dyspnea domain score is the mean of all non-missing responses for that domain. Only the dyspnea domain was measured as a secondary outcome. BL scores are the derived scores for each domain and total at Day 1 pre-dose. Change from BL was calculated as the average of the Day 168 values minus the BL value. Analysis performed used a repeated measures model with covariates of treatment, smoking status at screening (stratum), BL (derived scores at Day 1 pre-dose), day, day by BL, and day by treatment interactions.
| Scores on a scale | Placebo | FF/VI 50/25 µg OD | FF/VI 100/25 µg OD | FF/VI 200/25 µg OD |
|---|---|---|---|---|
| Mean Change From Baseline in Chronic Respiratory Disease Questionnaire Self-administered Standardized (CRQ-SAS) Dyspnea Domain Score at Day 168 | 0.09 ± 0.081 | 0.30 ± 0.080 | 0.43 ± 0.079 | 0.37 ± 0.080 |
Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of the study medication to the end of treatment (up to Week 24).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 14/162 (8.6%) | 27/162 (16.7%) |
| FF/VI 50/25 µg OD | — | 9/160 (5.6%) | 33/160 (20.6%) |
| FF/VI 100/25 µg OD | — | 7/161 (4.3%) | 34/161 (21.1%) |
| FF/VI 200/25 µg OD | — | 14/160 (8.8%) | 40/160 (25%) |
| Event | Placebo | FF/VI 50/25 µg OD | FF/VI 100/25 µg OD | FF/VI 200/25 µg OD |
|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 7/162 | 3/160 | 3/161 | 8/160 |
| PneumoniaInfections and infestations | 3/162 | 2/160 | 0/161 | 2/160 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/162 | 0/160 | 0/161 | 1/160 |
| Acute myocardial infarctionCardiac disorders | 1/162 | 1/160 | 0/161 | 0/160 |
| Acute coronary syndromeCardiac disorders | 0/162 | 0/160 | 0/161 | 1/160 |
| Cardiac failure acuteCardiac disorders | 0/162 | 0/160 | 0/161 | 1/160 |
| Cardiac failure congestiveCardiac disorders | 0/162 | 0/160 | 0/161 | 1/160 |
| Burns third degreeInjury, poisoning and procedural complications | 0/162 | 1/160 | 0/161 | 0/160 |
| Head injuryInjury, poisoning and procedural complications | 0/162 | 0/160 | 0/161 | 1/160 |
| Cerebrovascular disorderNervous system disorders | 0/162 | 0/160 | 0/161 | 1/160 |
| Event | Placebo | FF/VI 50/25 µg OD | FF/VI 100/25 µg OD | FF/VI 200/25 µg OD |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 7/162 | 13/160 | 9/161 | 19/160 |
| Upper respiratory tract infectionInfections and infestations | 15/162 | 16/160 | 19/161 | 14/160 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/162 | 2/160 | 6/161 | 3/160 |
| HypertensionVascular disorders | 1/162 | 1/160 | 2/161 | 5/160 |
| PyrexiaGeneral disorders | 5/162 | 3/160 | 4/161 | 3/160 |
| Age, Continuous(Years) | Placebo | FF /VI 50/25 µg OD | FF/VI 100/25 µg OD | FF/VI 200/25 µg OD | Total |
|---|---|---|---|---|---|
| Mean | 64.7 ± 8.78 | 65.2 ± 8.41 | 65.1 ± 9.19 | 62.7 ± 8.65 | 64.4 ± 8.80 |
| Gender(Participants) | Placebo | FF /VI 50/25 µg OD | FF/VI 100/25 µg OD | FF/VI 200/25 µg OD | Total |
|---|---|---|---|---|---|
| Female | 16 | 16 | 12 | 15 | 59 |
| Male | 146 | 144 | 149 | 145 | 584 |
| Race/Ethnicity, Customized(Participants) | Placebo | FF /VI 50/25 µg OD | FF/VI 100/25 µg OD | FF/VI 200/25 µg OD | Total |
|---|---|---|---|---|---|
| Asian - East Asian Heritage | 151 | 149 | 150 | 148 | 598 |
| Asian - South East Asian | 11 | 11 | 11 | 12 | 45 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Apr 2011, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2014, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone furoate · Vilanterol
Pulmonary Disease, Chronic Obstructive →